Loading insider details...
Beta
Latest Form 4 (Sep 9, 2026): Sale of 1,600 NAMS shares, $40.5K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 9, 2026 | NewAmsterdam Pharma Co N.V. (NAMS) | Sale | 1,600 | $40.5K |
| Aug 4, 2026 | MBX Biosciences, Inc. (MBX) | Grant/Award | 28,000 | n/a |
| Jul 2, 2026 | GENELUX Corp (GNLX) | Sale | 12,000 | $34.9K |
| Jun 18, 2026 | GENELUX Corp (GNLX) | Grant/Award | 28,409 | n/a |
| Jan 10, 2026 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/Award | 3,400 | n/a |
| Aug 29, 2025 | GENELUX Corp (GNLX) | Grant/Award | 22,283 | n/a |
| Jan 8, 2025 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/Award | 6,960 | n/a |
| Aug 5, 2024 | GENELUX Corp (GNLX) | Grant/Award | 39,541 | n/a |
| Jun 8, 2024 | GENELUX Corp (GNLX) | Purchase | 6,250 | n/a |
| Feb 15, 2024 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/Award | 2,793 | n/a |